434 related articles for article (PubMed ID: 31050375)
1. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
[TBL] [Abstract][Full Text] [Related]
2. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
Chen M; Liu B; Xiao J; Yang Y; Zhang Y
Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
[TBL] [Abstract][Full Text] [Related]
3. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
4. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
7. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
[TBL] [Abstract][Full Text] [Related]
8. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
[TBL] [Abstract][Full Text] [Related]
10. Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma.
Ye J; Liu H; Xu ZL; Zheng L; Liu RY
J Clin Lab Anal; 2019 Nov; 33(9):e22990. PubMed ID: 31402485
[TBL] [Abstract][Full Text] [Related]
11. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
12. A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma.
Liao M; Liu Q; Li B; Liao W; Xie W; Zhang Y
Cancer Sci; 2018 Dec; 109(12):4033-4044. PubMed ID: 30290038
[TBL] [Abstract][Full Text] [Related]
13. An integrated mRNA-lncRNA signature for relapse prediction in laryngeal cancer.
Xiang Y; Li C; Liao Y; Wu J
J Cell Biochem; 2019 Sep; 120(9):15883-15890. PubMed ID: 31062433
[TBL] [Abstract][Full Text] [Related]
14. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.
Mu L; Ding K; Tu R; Yang W
J Transl Med; 2021 Mar; 19(1):127. PubMed ID: 33771173
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
16. An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer.
Tu Z; He D; Deng X; Xiong M; Huang X; Li X; Hao L; Ding Q; Zhang Q
Oncol Rep; 2016 Jul; 36(1):215-22. PubMed ID: 27222340
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
[No Abstract] [Full Text] [Related]
19. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
20. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
Wu L; Wen Z; Song Y; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
